Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
NVAX has been in the news recently: Novavax's Covid-19 vaccine, Nuvaxovid, has received approval for use in individuals aged 65 and older, as well as high-risk groups, with commercial delivery anticipated this fall. Despite a decline in market sentiment indicated by the CNN Money Fear and Greed index, U.S. stock futures were slightly lower on Tuesday.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
